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Prostaglandin Es-9-oxoreductase (PGEz-9-OR), the enzyme which converts prostaglandin Es (PGEz) to 
prostaglandin Fh (PGFk), has been detected in human decidua Vera. A 105-fold purification was achieved 
when the centrifuged homogenate was fractionated sequentially by DEAE-Trisacryl, hydroxyapatite- 
agarose gel, ultrogel AcA 44 and Matrex gel blue A gel chromatographies. The following kinetic constants 
for PGE2-9-OR have been obtained. The equilibrium constant with respect to PGEz is 83 FM, the 
Michaelis constant, &,, for PGE2 is 80 PM, for NADPH 1.6 pM. The maximal velocity for the forward 
reaction is V, = 203 pmol/min. The enzyme was inhibited by progesterone, oestradiol-l7@, cortisol and 
pharmaceutical drugs. An activating effect could be demonstrated with Ca2’ and oxytocin. The occurrence 
of PGEz-9-OR in the decidua vera suggests that this enzyme may be responsible for the transformation 
of PGE2 to PGFb in these tissues. This may be an important mechanism for the initiation and main- 
tenance of uterine contractions. 
Enzyme p~rif~catian Human decidua vera 
1. INTRODUCTION 
Prostaglandin Ez-9-oxoreductase (FGEz-g-OR), 
the enzyme system which converts prostaglandin 
Ez (PGEz) to prostaglandin Fza (PGFh), has been 
identified in several tissues [l-7]. PGEz-9-OR ex- 
ists in multiple forms 181. A purification of about 
IO&fold has been achieved from porcine kidney 
[8]. The conjugate of PGA2 and glutathione seems 
to be a better substrate for PGEz-9-OR from the 
kidneys of chicken [9] and rabbits [lo] than PGEz. 
taglandins in amniotic fluid, maternal plasma [12] 
and uterine decidua Vera [13]. Moreover, pros- 
taglandins, when administered to pregnant women 
at any stage of gestation, induce labour and 
delivery [ 141. 
The biological importance of that enzyme may 
be the regulation of the PGEz/PGFs ratio in cells. 
The PGEz/PGFs ratio may play a critical role in 
many biological systems; e.g., contractibility may 
depend on the availability of sufficient PGFk. 
PGEz and PGFE, have been detected in uterine 
tissues and the highest concentrations have been 
found in the decidua vera Ill]. 
The metabolism of prostaglandins in the decidua 
Vera, a tissue that is contiguous with the uterine 
myometrium, may be of signal importance in the 
metabolic events that lead to the myometrial con- 
tractions of labour in women. The PGE2-POR, 
which has yet to be defined in human decidua vera 
tissues, may play a crucial role. 
Here we sought to evaluate this enzyme. A 
method of purification and some properties are 
described. 
2. MATERIALS AND METHODS 
Shortly before and during labour in the human 
there are striking increases in the levels of pros- 
2.1. Enzyme ~~ri~cati~n 
Human placentae obtained immediately after 
delivery were chilled on ice. Decidual tissues were 
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prepared as in [15] by sharp dissection. 
Histological examination proved that the decidual 
tissues were not contaminated with chorion laeve. 
The tissues from 11 placentae were washed several 
times with an ice-cold solution of 10 mM phos- 
phate buffer (pH 7.1) containing 1 mM EDTA 
(sodium salt), 1 mM dithiothreitol and 0.02% 
sodium azide (buffer A). The tissues were cut into 
small pieces and homogenized in a Potter 
Elvehjem homogenizer. The tissue to buffer ratio 
was 1 :4 (w/v). All purification steps were carried 
out at 0-4°C. The homogenates were centrifuged 
at 12000 x g for 15 min and the resulting superna- 
tant fractions were recentrifuged at 105000 x g for 
60 min in a Beckman ultracentrifuge model 
L 5.50. The combined supernatants (fraction 1) 
were concentrated to 25 ml with an Amicon 
ultrafiltration system (PM 10 membrane from 
Amicon, Witten, FRG). Concentrated fraction 1 
was applied to a 28 x 1.6 cm column of 
DEAE-Trisacryl M (LKB, Bromma, Sweden), 
which had been equilibrated with buffer A. The ef- 
fluent fractions were pooled (fraction 2) and con- 
centrated immediately to 8.5 ml with the aid of an 
ultrafiltration cell as described above. 
Fraction 2 was applied to a 20 x 1 cm column of 
hydroxyapatite-agarose gel (LKB) which was 
equilibrated with buffer A without EDTA, with 
20% glycerol (v/v) (buffer B). Enzyme fractions 
were eluted with the same medium, combined 
(fraction 3) and concentrated by ultrafiltration to 
7.9 ml as described above. The concentrated 
material from the previous step was applied to a 93 
x 2.6 cm column of ultrogel AcA 44 (LKB) 
equilibrated with buffer B that contained 0.1 M 
NaCl (buffer C). The eluents (fraction 4) were 
combined and concentrated by ultrafiltration to 
6.0 ml as described above. 
Concentrated fraction 4 was applied to a 26 x 
1.6 cm column of Matrex gel blue A (Amicon) 
which had been equilibrated previously with buffer 
B. The elution was started with 90 ml of the same 
medium followed by a linear gradient (one buffer 
chamber contained 90 ml buffer B and the other 
chamber 90 ml buffer B with 1 M NaCI). 
Fractions with the highest specific activity were 
pooled (fraction 5) and concentrated by ultrafiltra- 
tion to 5.5 ml as described above. The enzyme was 
dialyzed against buffer A and stored in aliquots at 
- 18°C. 
2.2. Enzyme activity 
PGEZ-9-OR was measured by a radioim- 
munological method. The standard assay mixture 
contained 100 mM Tris-HCl buffer (pH 8.0), 
1OpM NADPH, 71 /cM PGEz and IO-100,~l en- 
zyme solution in a final volume of 1 ml. All assays 
were conducted with blank controls with 
denatured enzyme preparations (boiled for 30 min 
at 95°C). The reaction was allowed to proceed at 
37°C for 60 min and terminated by adjusting the 
pH to 3.5 with 1.5 M citric acid. The samples were 
processed as in [ 161. 
PGFh was identified by a highly specific an- 
tiserum [17], on TLC plates [18] and by high- 
performance liquid chromatography [191 (LKB). 
For the kinetic studies different substrate con- 
centrations were employed as indicated in section 
Table 1 
Purification of PGEz-9-OR from the decidua vera from 4 fresh human term placentae 
Fraction Volume 
(ml) 
Protein Activity Specific Enrichment Yield 
(mg) (pmol/m’in) activity (To) 
(pm01 f 
min-’ . 
rng-‘) 
105000 x g supernatant 94 80.80 289 3.6 _ 100.0 
Eluate of DEAE-Trisacryl M 69 40.00 211 5.3 1.5 73.0 
Eluate of hydroxyapatite-agarose gel 94 11.10 182 16.4 4.6 62.9 
Eluate of ultrogel AcA 44 153 4.20 163 38.8 10.8 56.4 
Eluate of Matrex gel blue A 42 0.05 19 380.0 105.3 6.6 
Throughout purification, enzyme activity was assayed as described in the text by following the production of PGFh 
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Fig. 1. Polyacrylamide gel electrophoresis patterns of 
prostaglandin E2-Poxoreductase. The protein was 
stained with Coomassie blue. From left to right are 
shown the individual purification steps (1-5). (c) 
Prostaglandirr Ez-9-oxoreductase. 
3. One unit of enzyme activity is defined as the 
amount of enzyme that catalyzes the production of 
1 pmol PGFh/min under standard assay condi- 
tions. Total protein was determined as in [20]. 
3. RESULTS 
Table 1 illustrates the individual purification 
steps of the decidual PGEz-g-OR, which resulted in 
105-fold enrichment. Polyacrylamide gel elec- 
trophoresis of the last step revealed an almost 
homogeneous protein fraction (fig.1). An Mr of 
approx. 33000 could be established by gel filtra- 
tion. The pH optimum for the forward reaction 
was 8.3. The kinetic studies were performed with 
fraction 5. Initial velocities were measured and the 
enzyme constants calculated as in [21]. Evaluation 
Table 2 
Kinetic constants 
Equilibrium Michaelis Maximum 
constant, constant, velocity, 
Vl 
(pmol/min) 
PGE2 83.0 80.5 203.0 
NADPH 0.9 1.6 
Material from fraction 5 was used for the kinetic studies. 
The enzyme constants were calculated as in [21] 
Table 3 
Effects of various compounds on PGEz-9-OR activity in 
human decidua vera tissues 
Compound Remaining 
(1 mM) activity (olo) 
None 100 
Progesterone 31 
Oestradiol-17fi 51 
Cortisol 45 
Vitamin D3 72 
Aspirin 35 
Indomethacin 19 
Lonazolac 22 
Oxytocin 119 
Ca2+ 115 
The enzyme activity was assayed as described in the text 
by following the production of PGFti 
of the primary and secondary plots provided the 
constants listed in table 2. 
The effects of several biologically occurring 
compounds and pharmaceutical drugs are listed in 
table 3. The enzyme was inhibited by progesterone, 
oestradiol-17@, cortisol, aspirin, indomethacin and 
lonazolac (Irritren, Byk Gulden, Konstanz, FRG). 
An activating effect could be demonstrated with 
Ca2+ and oxytocin. 
4. DISCUSSION 
The enzyme PGEz-9-OR has been mainly 
isolated from the kidney [4,8,22]. The activity of 
the enzyme in human decidua vera tissues has yet 
to be described. This study demonstrates clearly 
that PGEz-9-OR is localized mainly in the cytosolic 
fractions of decidual tissues. 
In view of the physiological and clinical impor- 
tance of these findings, the ability of the decidua 
to synthesize PGFti from PGEz suggests that this 
tissue may play a crucial role in the regulation of 
labour in women. PGEz-9-OR prefers NADPH as 
a cofactor and is therefore independent of the 
15-hydroxyprostaglandin dehydrogenase which is 
present in high concentrations in the human 
placenta [23]. 
The isolation of PGEZ-POR revealed a 105-fold 
purification, which is comparable with other 
reports [8]. Since there might be a specific inhibitor 
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of PGEZ-9-OR in the placenta [24] the estimation 
of enzyme activity in crude fractions seems to be 
unreliable. In the 105000 x g supernatant he en- 
zyme activity is readily measured and therefore 
reflects the starting point. Bisubstrate kinetics give 
the most reliable values for enzymes that require 
two substrates. According to [21] 5 different 
kinetic constants can be obtained. 
The K,,, values of the substrates were in good 
agreement with those found in porcine kidney 
PGEz-9-OR [8]. The observation that boiled 
placental fractions seem to contain a specific in- 
hibitor of PGEz-9-OR suggests that the enzyme 
function is regulated. 
The present preliminary attempts to describe this 
inhibitor point towards steroids. Equimolar 
amounts of progesterone, oestradiol-17@ and cor- 
tisol inhibit PGEz-9-OR activity by about 50% 
(table 3). Interestingly, the same was true for the 
analgetics aspirin, indomethacin and lonazolac to 
various degrees (table 3). Vice versa, Ca2+ and ox- 
ytocin seem to stimulate PGEZ-POR. These find- 
ings could be very important for the regulation of 
parturition in the human. 
In conclusion, this study demonstrates the 
presence of PGEz-9-OR in the decidua vera which 
may be controlled by a variety of compounds. The 
role of steroids, analgetics and possibly a number 
of other compounds, remains to be defined in 
detail. 
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